Patients to benefit from updated skin tumour publications
26 October 2018
Healthcare professionals specialising in skin cancers, including melanoma, now have access to two publications with the most current information relating to skin tumour diagnosis and management. Both publications – the WHO Classification of Skin Tumours, 4th Edition, and Pathology of Melanocytic Tumours – are co-edited by Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia (MIA), and will have a major impact on the diagnosis and management of melanoma and other skin tumours.
The WHO Classification of Skin Tumours, 4th Edition integrates diagnostic information and pathological features of skin tumours with the latest in molecular, genetic and epidemiological information. This edition of the WHO Skin Blue Book has substantially updated the classification of melanoma and is a breakthrough publication that every pathologist, dermatopathologist, dermatologist, oncologist and other health care professionals who deal with skin tumours should have.
A separate textbook Professor Scolyer has edited with other world authorities from the USA is Pathology of Melanocytic Tumours. Constituting a large percentage of everyday diagnostic practice, melanocytic pathology is a complex and challenging area with many difficult-to-diagnose lesions. This highly illustrated reference, written by three of the world’s leading dermatopathologists, provides authoritative guidance in the accurate diagnosis of even the most challenging pigmented skin tumours.
‘These publications will undoubtedly assist the care of patients with melanoma and other skin cancers world-wide,” Professor Scolyer said.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
A round of applause for a well deserved win.
A message from our CEO, Carole Renouf
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.
Melanoma Institute Australia's annual fundraising initiative is all systems go!
The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.
Updated guidelines defining appropriate excision margins have been published thanks to research from MIA.
Joanne and her trusty companion Frankie spend their days spreading a message of hope in hospitals, nursing homes, even prisons. It is a long way from her darkest hour facing palliative care. This is her story of hope.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.